1200px-Yale_University_logo.svg

Join our Research Study on Recreational Opioid Use

Researchers at Yale University are evaluating the safety and tolerability of a potential new medication for recreational opioid use.

Fast Facts

21-50 years old

Use Opioids Recreationally

compensation provided

Conducted in connecticut

Study Background

This clinical research study aims to evaluate the effects of a medication (NYX-783) combined with Oxycodone in recreational opioid users. Participation involves one three-week stay at our inpatient research unit OR seven separate three-day stays. Eligible participants will receive up to $2,000 for completing this study.

HIC #2000033008

Additional Information

This study aims to evaluate the safety, tolerability, and pharmacokinetics of a medication combined with Oxycodone in recreational opioid users. The results of the study may benefit science and others through increasing our knowledge about the study drug NYX-783 and its effects in combination with taking opiates such as Oxycodone.

You may qualify for this study if you meet the following criteria:

  • Between the ages of 21-50
  • Recreational opioid user (not intravenously, no OUD, no history of overdoses or detoxification)
  • Have never taken Methadone or Suboxone
  • Medically healthy
  • No prescribed sedatives or stimulants
  • No significant substance use disorder other than nicotine
  • Not pregnant or breast feeding
  • No history of HIV or Hepatitis¬†
  • No traumatic brain injury or seizure disorder

If you decide to participate in this clinical research study you will attend 1 in-person screening visit, lasting approximately 2-3 hours, to determine medical and psychiatric eligibility. Eligible participants will be admitted to our inpatient research unit for a total of 3 weeks OR 7 separate 3-day long stays.

During admissions, your vital signs will be monitored (e.g., heart activity, breathing, oxygen levels) and subjective state (e.g., mood) throughout the day and evening to evaluate the effects of the study medication.

Eligible participants can receive up to $2,000 for their participation.

There is no cost to participate in this study.